

FRESENIUS KABI NewsFeed

Summer 2025

Welcome to the latest edition of Fresenius Kabi NewsFeed.
Fresenius Kabi NewsFeed contains brand information and promotional content.

Enteral Nutrition

- 03. NEW PRODUCT
Fresubin® PLANT-BASED Drink
- 04. Fresenius Kabi high protein tube feed range
- 05. Saving plastic with EasyBag tube feeds
- 06. Change of enzyme in our hydrolysed protein range
- 06. Discontinued products

Parenteral Nutrition

- 07. Lipids in parenteral nutrition (PN)
- expert consensus statements:
Translating guidelines into clinical practice
- 08. Connect Programme:
New module coming soon

Clinical Nutrition

- 09. Fresenius Kabi Advanced Nutrition Conference (FRANC) in oncology
- 09. MOTIV:
New COPD module coming soon





Welcome to the latest edition of Fresenius Kabi NewsFeed

The newsletter which provides you with a window into Fresenius Kabi enteral and parenteral nutrition.

Our Clinical Nutrition Scientific Affairs team have come together to offer a newsletter to disseminate clinical updates and provide a window into Fresenius Kabi enteral and parenteral nutrition, directly to healthcare professionals who deliver nutritional care. The aim is to provide both educational and product updates around clinical nutrition, including oral nutritional supplements (ONS), dysphagia, enteral tube feeds and feeding tubes, and parenteral nutrition products.

In this edition we look at our new product launch of Fresubin® PLANT-BASED Drink, as well as a closer look at the Fresubin® high protein tube feed range. We provide a handy reminder about PRO SUPPORT resources, and an update on the change of enzyme used in our hydrolysed protein ONS and tube feed range. We also share some insight on our efforts to reduce plastic usage in our enteral tube feeds. In parenteral nutrition, we take a look at the lipids in parenteral nutrition - expert consensus statements, as well as the new module coming soon to the Connect programme. We also cover highlights from our recent study event, the 28th Fresenius Kabi Advanced Nutrition Conference (FRANC) held in Bad Homburg, Germany and announce a new module coming to our MOTIV eLearning platform.

If you have a colleague who would like to receive a copy of our Newsfeed Newsletter - please ask them to register using the QR code below:



SCAN TO REGISTER

Adverse events should be reported. Reporting forms and information can be found at: <http://yellowcard.mhra.gov.uk> Adverse events should also be reported to Fresenius Kabi Limited. Email: pharmacovigilance.gb@fresenius-kabi.com





Fresubin®

PLANT-BASED Drink

NEW!

THE ONLY HIGH PROTEIN PLANT-BASED ONS¹

£1.60
Per Bottle

Fresubin PLANT-BASED Drink is a nutritionally complete oral nutritional supplement (ONS) for the dietary management of patients with or at risk of disease related malnutrition, in particular those with increased energy and protein needs, and those requiring a plant-based diet.

High energy, density 1.5 kcal/ml	Compliance to ONS increases with energy density ^{2,3}
High protein 15 g per bottle (20 % energy)	High protein ONS support the reduction in complications and hospital length of stay and improved hand grip strength ⁴
Contains 15g soya protein	Contains high quality soya protein suitable for vegan and plant-based diets
Contains 4.6g fibre per bottle (3 % energy)	Contains fibre to support a healthy gut functions ⁵
High in Vitamin D 7.6µg per bottle	Vitamin D to support bone health and help reduce fracture risks ⁶⁻⁸

Fresubin® PLANT-BASED Drink
Vanilla Flavour
Smak Vanilj
300 kcal
1.5 kcal/ml
15g Protein
Energirik + Protein med fiber
FRESINIUS KABI

Fresubin® PLANT-BASED Drink
HIGH PROTEIN
100% SOYA PROTEIN
GLUTEN & LACTOSE FREE

VEGAN

References

1. MIMS online. www.mims.co.uk. Accessed June 2025 2. Nieuwenhuizen WF et al. Older Adults and patients in need of nutritional support: review of current treatment options and factors influencing nutritional intake, Clin Nutr. 2010;29(2):160-9 3. Hubbard et al. A systematic review of compliance to oral nutritional supplements. Clin Nutr. 2012; 31(3) 293-312 4. Cawood et al. Systematic review and meta-analysis of the effects of high protein oral nutritional supplements. Ageing Res Rev. 2012;11(2):278-96 5. Lochs H, et al. Introductory to the ESPEN Guidelines on Enteral Nutrition: Terminology, definitions and general topics. Clin Nutr. 2006 Apr;25(2):180-6. doi: 10.1016/j.clnu.2006.02.007. Epub 2006 May 11. PMID: 16697086. 6. Scientific Advisory Committee on Nutrition (SACN). Vitamin D and health 2016 7. Bischoff- Ferrari et al. Falls prevention with supplemental and active forms of Vitamin D: a meta-analysis of randomised controlled trials BMJ 2009;339:b3639 8. Bischoff- Ferrari et al. A pooled analysis of Vitamin D dose requirements for fracture prevention. N Engl J Med 2012 367(1):40-9

Fresenius Kabi are excited to introduce

+PRO SUPPORT



A comprehensive support package designed to support patient compliance and their journey to recovery with Fresubin® PRO COMPACT Drink, delivering added value to meet your patients' needs.

Explore the full PRO SUPPORT resources and discover how they can support your patient's to optimise their nutritional intake and reach their treatment goals.

For more information about these resources visit our dedicated patient website:

<https://www.fresubin.com/gb/resources/pro-support>




Fresenius Kabi

High protein tube feed range


Fresenius Kabi provide a broad range of high protein tube feeds developed to meet the individual nutritional needs of patients with or at risk of disease related malnutrition and a wide range of physiological conditions or diseases.

An ageing population and the impact of chronic long-term conditions on nutritional status have been recognised by ESPEN¹ and PROT-AGE² as key factors in the need for higher protein requirements.

The Fresubin® and Survimed® high protein tube feed range are designed to support the needs of patients, from critical care, to hospital wards and back into the community.



Recommendations from the PROT-AGE Study Group and the ESPEN Expert Group for protein intake in older adults in g protein/kg body weight/day^{1,2*}



Features of the high protein range include:

- A range of energy contents (1.0-2.0 kcal/ml)
- A range of protein contents (20 - 33% of energy)
- Addition of EPA and DHA from fish oil to all tube feeds
- Fibre versions containing a mixed fibre blend,
- Options available with adapted fat blends and/or hydrolysed whey protein for patients with malabsorption
- All presented in an Easybag, with a unique resealable membrane providing a reliable and convenient way to deliver enteral nutrition.

References

1. Deutz NEP, et al. Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN expert Group. 2014. Clinical Nutrition; 33: 929-936.
 2. Bauer J, et al. evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. 2013. J am med dir assoc.; 14(8): 542-559.
- * Caution needed in patients with alteration of kidney function
EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid)




Saving plastic with EasyBag...


Committed to minimising plastic

Fresenius Kabi are committed to minimising plastic usage in our packaging, as preventing plastic waste is the most favoured option for our planet.¹

The benefits of plastics are particularly apparent in medicine, being soft, transparent, and flexible serving as innovative materials in medical applications.² Compared to other packaging materials, it is cost-effective, energy-efficient to produce, and lightweight. However, increased use has led to significant plastic waste.³ This is why Fresenius Kabi are taking steps to reduce our plastic usage, recognising the importance of preventing waste in the first place.



By choosing carefully, you can help to reduce the impact of enteral nutrition packaging waste on the environment.



EasyBag is the simple solution

Compared to an average tube feed bottle on the market, Easybag is the lightest container and saves 60% of plastic used in weight and 85% of plastic waste generated in volume.*

References

1. European Commission 2016. Directive 2008/98/EC on waste (Waste Framework Directive). https://environment.ec.europa.eu/topics/waste-and-recycling/waste-framework-directive_en. [Accessed June 2025] 2. North E.J., Halden R.U. Plastics and environmental health: the road ahead. *Rev Environ Health*. 2013;28(1):1-8. doi: 10.1515/reveh-2012-0030. PMID: 23337043; PMCID: PMC3791860. 3. World Environment Day 2023: Solutions for healthcare plastic pollution [Internet]. Centre for Sustainable Healthcare. 2023. Available from <https://sustainablehealthcare.org.uk/blog/world-environment-day-2023-healthcare-plastic-pollution>. [Accessed June 2025]

*Unpublished study with representative tube feed bottles.

† Average weight of a tube feed bottle.

Change of enzyme in our Survimed® and Fresubin® Intensive range

Fresenius Kabi have started the change to substitute the enzyme used in hydrolysis of the protein source in our Survimed OPD range and Fresubin Intensive. This change means that these products will become halal certified.

The enzyme used in Survimed® OPD Drink and Survimed® OPD tube feed has already changed and this update is now reflected in our 'Allergen and Dietary Information' table. As the rest of the range switch, we will update the table.

The 'Allergen and Dietary Information' table can be accessed via our website and via the Enteral Nutrition Product App

Scan to download the Enteral Nutrition Product App



Discontinued products

Fresenius Kabi have taken the decision to discontinue **Fresubin® Original Drink Peach and Chocolate flavour**. We hope this does not cause too much inconvenience for you or your patients.

For details of our full range of oral nutritional supplements and suitable alternatives, please visit our website:

www.fresenius-kabi.com/gb/healthcare-professional-area/clinical-nutrition/enteral-nutrition/fresubin-ons-ready-to-drink

where you will find further product information.



Lipids in parenteral nutrition (PN) - expert consensus statements: Translating guidelines into clinical practice

The Lipids in PN Summit involved a panel of international experts from 9 countries, with extensive clinical experience in the use of intravenous lipid emulsions (ILEs) in various clinical settings. Expert consensus statements were provided, helping to bridge gaps between evidence and clinical practice, and thus complementing formal PN guideline recommendations.

The summit was divided into:

1

Scientific discussion

- The emerging concept of bioactive lipid mediators
- Critical evaluation of the biological effects of lipids included in PN formulations

2

Clinical aspects

- Concerning the use of ILEs in adult patients requiring PN
- During the meeting, a set of consensus statements were developed.

Summary of key messages



Fish oil, rich in eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) with inflammation-resolving and immunomodulatory properties, has become an important component of composite ILEs for PN.



PN including fish oil containing ILEs as a source of EPA and DHA represents a key strategy to promote resolution physiology in clinical practice.

Systemic inflammation is common during critical illness and post-surgery, and the capacity and timing of resolution can affect patient outcomes.¹ Resolution of inflammation is triggered by specialised pro-resolving mediators (SPMs). EPA and DHA from fish oil are substrates for the synthesis of SPMs.²



This International Lipid Summit was funded by Fresenius Kabi GmbH

[Read full text here](#)

Published Online 21st January 2025



Fish oil containing ILEs have clinically meaningful advantages over standard intravenous lipid emulsions for adult ICU and hospitalised patients.

Fish oil containing ILEs showed significant benefits on clinical outcomes over standard ILEs without fish oil in meta-analyses.³⁻⁸



The use of fish oil containing ILEs represents a cost-effective strategy.

Cost considerations may impact lipid emulsion choice. A meta-analysis with cost-effectiveness analysis showed that PN with fish oil containing ILEs represents cost-saving benefits across different health care systems.⁹



Recommended daily fish oil dose in PN for adult medical and surgical ICU and surgical and hospitalised patients is 0.1 - 0.2g/kg/day.

Based on currently available clinical data, recommended fish oil doses provided by lipid emulsions containing fish oil should be between 0.1-0.2g/kg/day for adult critically ill, surgical and hospitalised patients requiring parenteral nutrition.^{10,11}

References

1. Cioccarl L, Luethi N, Masoodi M. Lipid mediators in critically ill patients: a step towards precision medicine. *Front Immunol*. 2020;11:599853.
2. Martindale RG, Calder PC, Cogle SV et al. Lipids in parenteral nutrition: Translating guidelines into clinical practice. *Clinical Nutrition Open Science*, 60; April 2025, 50-65
3. Zhao Y, Wang C. Effect of ω -3 polyunsaturated fatty acid supplemented parenteral nutrition on inflammatory and immune function in postoperative patients with gastrointestinal malignancy: a meta-analysis of randomized control trials in China. *Medicine (Baltimore)* 2018;97(16):0472.
4. Pradelli L, Mayer K, Klek S, Omar Alsaleh AJ, Clark RAC, Rosenthal MD, et al. ω -3 fatty acid enriched parenteral nutrition in hospitalized patients: systematic review with meta-analysis and trial sequential analysis. *JPEN J Parenter Enteral Nutr* 2020;44(1):44-57.
5. Pradelli L, Klek S, Mayer K, Omar Alsaleh AJ, Rosenthal MD, Heller AR, et al. Omega-3 fatty acid containing parenteral nutrition in ICU patients: systematic review with meta-analysis and cost-effectiveness analysis. *Crit Care* 2020;24(1):634.
6. Xu XT, Huang H, Tian MX, Hu RC, Dai Z, Jin X. A four-oil intravenous lipid emulsion improves markers of liver function, triglyceride levels and shortens length of hospital stay in adults: a systematic review and meta-analysis. *Nutr Res* 2021;92: 1-11.
7. Notz Q, Lee ZY, Menger J, Elke G, Hill A, Kranke P, et al. Omega-6 sparing effects of parenteral lipid emulsions—an updated systematic review and meta-analysis on clinical outcomes in critically ill patients and meta-analysis on clinical outcomes in critically ill patients. *Crit Care* 2022;26(1):23.
8. Pradelli L, Mayer K, Klek S, Rosenthal MD, Povero M, Heller AR, et al. Omega-3 fatty acids in parenteral nutrition - A systematic review with network meta-analysis on clinical outcomes *Clin Nutr* 2023;42(4):590-9.
9. Pradelli L, Klek S, Mayer K, Omar Alsaleh AJ, Rosenthal MD, Heller AR, et al. Cost-effectiveness of parenteral nutrition containing ω -3 fatty acids in hospitalized adult patients from 5 european countries and the US. *JPEN J Parenter Enteral Nutr* 2021;45(5):999e1008.
10. P. Singer, A.R. Blaser, M.M. Berger et al. ESPEN practical and partially revised guideline: Clinical nutrition in the intensive care unit. *Clinical Nutrition* 2023; 42 1671-1689
11. Martindale RG, Berlanda D, Boullata JI, Cai W, Calder PC, Deshpande GH, et al. Summary of proceedings and expert consensus statements from the international summit "Lipids in Parenteral Nutrition". *JPEN J Parenter Enteral Nutr* 2020; 44(Suppl 1):S7-20





CONNECT PROGRAMME: New Module Coming Soon!



Effective Communication and Wellbeing Strategies for Healthcare Professionals

Following the success of the Connect coaching courses, Fresenius Kabi are excited to announce the introduction of a new module offering healthcare professionals working within nutrition support teams the essential tools to enhance personal wellbeing and professional development.

During the four-week course, participants will learn practical steps for managing stress, improving emotional intelligence, and engaging in productive conversations, with both colleagues and patients. Emphasising the importance of influencing styles, non-judgmental listening, and managing conflict, this course will equip attendees with the skills to navigate difficult conversations, promoting positive outcomes and role modelling supportive behaviours in the workplace.

The course is intended for healthcare professionals working within nutrition support teams.

All sessions will be held on Microsoft Teams and will be interactive, involving tutor input, group discussions and practical case studies using virtual breakout rooms.

To register interest or find out more, please follow the **Fresenius Kabi LinkedIn page**, or email: admin@connectprogramme.co.uk

Created and funded by



Fresenius Kabi



Fresenius Kabi Advanced Nutrition Conference (FRANC) in Oncology


FRANC

Fresenius Kabi were pleased to hold the 28th Fresenius Kabi Advanced Nutrition Conference (FRANC) in Bad Homburg, Germany. The focus was oncology, providing high-level scientific information to healthcare professionals dealing with clinical nutrition within the field of oncology in their daily practice, and aimed to drive advancements in patient-centric oncology care through collaboration and innovation.

We were delighted to welcome over 100 healthcare professionals from over 33 countries, including 4 dietitians from the UK. Attendees included renowned oncologists, surgeons, and dietitians all working within the field of oncology. These professionals gathered to share knowledge; exchange insights and discuss best practice for nutritional management in oncology.

Dr Matti Aapro from Switzerland and Dr Vanessa Fuchs-Tarlovsky from Mexico chaired the 2-day conference, welcoming talks from other globally renowned names in nutrition including Dr Jann Arends, Prof. Stein Kaasa, Prof. Stanislaw Klek and Prof. Maurizio Muscaritoli. We also welcomed an inspiring talk from patient advocate, Robert Greene, on the patient's perspective of cancer treatment and explored how we can truly achieve patient-centred care.



Thank you to all those you attended.

You can find recordings from the conference on Fresenius Kabi's Nutrition Events platform using the QR code:

MOTIV[®]

Educate with Energy

Discover our range of evidence-based CPD-accredited clinical nutrition modules



Start your learning journey today!
www.motiv-elearning.com



▲ scan here ▲

Fresenius Kabi Limited,
 Cestrian Court, Eastgate Way, Manor Park,
 Runcorn, Cheshire WA7 1NT
 tel: 01928 533 516

scientific.affairsUK@fresenius-kabi.com
www.fresenius-kabi.com/gb

GB-FreONS-2500087
 Date of preparation: June 2025

If you feel you have received this by mistake or wish to unsubscribe from receiving any further newsletters, please email scientific.affairsUK@fresenius-kabi.com.

Data Protection: Protecting your privacy is important to us. You can find out more about how we process your data in our data protection statement [Data Protection - Fresenius Kabi Great Britain \(fresenius-kabi.com\)](#). If you have any concerns relating to the processing of your personal data, please contact our local data protection adviser at data.protection-UK@fresenius-kabi.com

